Manufacturer

ISK Biosciences Europe N.V.

Belgium ManufacturerЗаявитель ·isk-europe.com ↗
11
products
4
categories
1
country

Description

ISK Biosciences Europe, N.V. is a prominent European subsidiary of the Japanese multinational corporation Ishihara Sangyo Kaisha, Ltd. (ISK), a global leader in the agricultural chemical industry. Based in Belgium, the company serves as the strategic hub for research, development, and distribution of advanced crop protection solutions throughout the European market. With a deep-rooted commitment to innovation, the organization leverages the extensive technical heritage of its parent company, which has been at the forefront of chemical science since its establishment in 1920. Over the decades, the company has built a robust reputation for bridging sophisticated Japanese R&D with the specific regulatory and agricultural requirements of European growers.

The company specializes in the development and commercialization of high-performance agrochemicals, focusing on sustainable agricultural practices that ensure food security and crop yield efficiency. Their activities encompass a wide range of chemical solutions, including selective crop protection agents that help farmers manage complex field challenges while adhering to stringent European environmental standards. By prioritizing long-term efficacy and safety, ISK Biosciences Europe, N.V. maintains a strong market presence and is recognized for its reliability and technical support. Their operations are defined by a continuous focus on optimizing chemical efficacy, ensuring that modern agriculture can thrive through scientifically backed, high-quality inputs that support both industrial productivity and environmental stewardship.

О компании

Корпоративная семья

Входит в группу: ISHIHARA SANGYO KAISHA, LTD.

История владения
  • ISHIHARA SANGYO KAISHA, LTD. — ?–наст.
Контент-граф

Connections · ISK Biosciences Europe N.V.

Most often together:
Товары бренда

Products · 11

Reference

Other · Manufacturer

Community

Discussion

No discussions yet — be the first.